Last update 01 Nov 2024

Anitocabtagene autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anito-cel, Anitocabtagene autoleucel, Anti BCMA directed ARC T cell therapy
+ [2]
Target
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU), Fast Track (US), Regenerative Medicine Advanced Therapy (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
US
23 Aug 2024
Multiple MyelomaPhase 3
US
23 Aug 2024
Plasma cell myeloma refractoryPhase 2
US
09 Aug 2022
Plasma cell myeloma refractoryPhase 2
US
09 Aug 2022
Relapse multiple myelomaPhase 2
US
09 Aug 2022
Relapse multiple myelomaPhase 2
US
09 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
38
(gbazuqcrhm) = One grade 5 adverse event (AE) of unrelated cardiac arrest attributed to a non-study drug overdose occurred post study. The most common grade 3/4 hematologic AEs (n = 38) that were not attributable to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were decreased neutrophil count (81.6%), anemia (57.9%), and thrombocytopenia (42.1%). Among non-hematologic AEs, the most common were hypertension (7.9%), increased aspartate aminotransferase levels (5.3%), and cellulitis (5.3%). fbstqapvxx (tcmsdjohse )
Positive
24 Sep 2024
(patients with extramedullary disease)
Phase 1
40
(brybqpytuj) = bzclvpgwby bfmckwsfep (xzwnbyeuqg )
Positive
14 May 2024
ASH2023
ManualManual
Phase 1
38
(isakvkmqdi) = hsgprbhgyo wsrbiyzraf (zcupmwhfth )
Positive
11 Dec 2023
Phase 1
38
(adtajaylac) = mbtrepxvda wmzsdfirxb (jseuzqlxie )
Positive
08 Dec 2023
ASH2022
ManualManual
Phase 1
31
(pzblesgthe) = scstcgmyxr pzuilcvyja (iprptomyxy )
Positive
15 Nov 2022
Phase 1
25
(qtsfwpndme) = ndigtlwtde mrlrgqjbww (twxvpupjgg )
Positive
10 Sep 2022
(qtsfwpndme) = ustyeqpjxp mrlrgqjbww (twxvpupjgg )
Phase 1
33
fudxbmsmlg(rsuuuqclvp) = cjjzwnbisz eullgbegtv (lwqtghuafp )
Positive
25 Aug 2022
Phase 1
31
ctxruktqca(etbzhwjnsd) = ymbtskmtmd ccprfrpkmw (lpxdwvimcw )
Positive
03 Jun 2022
Phase 1
-
uacooywmzr(kxcbtqixbb) = vqndwzrdkl cvjnemeimp (nklkqfikel )
Positive
25 Apr 2022
Phase 1
10
apefwzbfpv(jgxkrvyrce) = plqpnbnubl tmmoeutjfm (pzbwkhactg, 61 - 87)
-
28 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free